Bristol-Myers Squibb (BMY) volatility flat at 20 into positive clinical results

Bristol-Myers Squibb (NYSE: BMY) is recently up 7.2% in pre-open trading following promising clinical results from stroke-preventing Eliquis. Deutsche Bank reiterated their Buy rating and $31.50 price target on BMY. Overall option implied volatility of 20 is near its six-month average according to Track Data.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
• Palo Alto Networks (PANW) call put ratio 1 call to 1.2 puts amid price movement
• CrowdStrike Holdings Inc. (CRWD) call put ratio 1 call to 1.1 puts amid price movement